Abstract |
Paraoxonase-1 (PON1) Q192R polymorphism was recently suggested to determine per se clopidogrel response on major cardiovascular events (MACEs). We assessed the impact of PON1, CYP2C19, and ABCB1 polymorphisms on MACE in clopidogrel-treated acute myocardial infarction (AMI) patients (N = 2,210), including those undergoing percutaneous coronary intervention (PCI) (n = 1,538). PON1 polymorphism was not associated with increased risk of in-hospital death and MACEs at 1 year (adjusted hazard ratio (HR) 1.03, 95% confidence interval (CI) 0.66-1.61 and adjusted HR 0.77, 95% CI 0.42-1.41 for QQ versus RR in all and PCI patients, respectively). The presence of two CYP2C19 loss-of-function (LOF) alleles was associated with the risk of in-hospital death and MACEs at 1 year in the overall population (adjusted odds ratio (OR) 3.67, 95% CI 1.05-12.80 and adjusted HR 1.96, 95% CI 1.08-3.54) and in PCI patients (adjusted OR 6.87, 95% CI 2.52-18.72 and adjusted HR 3.06, 95% CI 1.47-6.41). Unlike CYP2C19 polymorphism, PON1 (Q192R) polymorphism is not a major pharmacogenetic contributor of clinical response to clopidogrel in AMI patients.
|
Authors | T Simon, P G Steg, L Becquemont, C Verstuyft, S Kotti, F Schiele, E Ferrari, E Drouet, G Grollier, N Danchin |
Journal | Clinical pharmacology and therapeutics
(Clin Pharmacol Ther)
Vol. 90
Issue 4
Pg. 561-7
(Oct 2011)
ISSN: 1532-6535 [Electronic] United States |
PMID | 21918510
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Clopidogrel
- Aryldialkylphosphatase
- PON1 protein, human
- Ticlopidine
|
Topics |
- Aged
- Aged, 80 and over
- Aryldialkylphosphatase
(genetics)
- Clopidogrel
- Female
- Follow-Up Studies
- Genotype
- Hospital Mortality
(trends)
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy, genetics, mortality)
- Polymorphism, Genetic
(genetics)
- Prospective Studies
- Registries
- Ticlopidine
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|